Page 33 - Noble-Virtual-Healthcare-2024

Immunic, Inc.

SELECTED FINANCIAL ITEMS IMUX

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (27.25) (25.02) (23.57) (23.38) (99.22)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (25.27) (24.00) (22.77) (21.57) (93.61)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 108.87 88.74 66.98 54.30 54.30
Cash & Short Term Investments 92.76 77.29 59.69 46.67 46.67
% of Assets 85% 87% 89% 86% 86%
Current Assets -Total 106.58 86.55 65.23 52.53 52.53
% of Assets 98% 98% 97% 97% 97%
Total Liabilities 17.65 19.46 18.57 25.37 25.37
% of Assets 16% 22% 28% 47% 47%
Current Liabilities - Total 16.30 18.24 17.78 24.73 24.73
% of Assets 15% 21% 27% 46% 46%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 91.22 69.28 48.41 28.93 28.93
% of Assets 84% 78% 72% 53% 53%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (19.51) (19.98) (17.31) (14.03) (70.83)
Net Cash Flow - Investing 5.34 4.34 (0.04) (0.17) 9.46
Net Cash Flow - Financing 0.05 0.10 0.28 0.60 1.03

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference